PacBio Expands Distribution In China, Partnering With Haorui Gene To Access New Clinical Lab Networks

PacBio, a leading provider of highly accurate sequencing solutions, has announced the appointment of Haorui Gene as its official distributor in China. Haorui Gene is a well-known expert in blood typing genomics, and this partnership aims to increase access to PacBio’s HiFi long-read sequencing technology for both clinical and research use, especially in transfusion medicine and hematology, where precise and complete genomic data are essential for patient care.

Since its founding in 2020, Haorui Gene has become a major player in blood typing genomics in China. The company operates seven Sequel II and three Revio sequencing systems nationwide to support large projects in HLA typing, blood group genotyping, and the discovery of rare blood types. Their work has improved standards for accuracy and reliability in analyzing complex genomic regions that traditional methods often miss.

This collaboration is a key move toward making PacBio’s HiFi sequencing the preferred method for blood genomics. The technology provides exceptional accuracy in reading full-length genes, detecting structural variants, and analyzing highly variable regions important for transfusion safety and donor matching. Haorui Gene’s efforts have already led to over 20 peer-reviewed publications and widespread use of long-read sequencing in Chinese blood centers, showing strong clinical and scientific support for this advanced technology in personalized transfusion medicine.

Christian Henry, President and Chief Executive Officer of PacBio, “This arrangement formalizes a strong foundation and supports our broader goal to make accurate, long-read sequencing standard practice in clinical genomics. Haorui Gene has built deep expertise in one of the most genomically complex areas of medicine. Their leadership in blood group and HLA typing, paired with our HiFi technology, has already delivered real progress in China, making them an ideal partner to help scale access to our highly accurate long-read sequencing technologies across China. We are excited to work together to continue building momentum in critical areas of clinical genomics like transfusion medicine.”

Wang Bo, General Manager of Haorui Gene, stated, “Together with PacBio, we are committed to delivering high-standard clinical diagnostics and expanding the frontiers of long-read sequencing in healthcare. This collaboration reinforces our shared goal of enabling transformative discoveries in hematology and beyond.”

Under the agreement, Haorui Gene will distribute PacBio’s Vega platform across China. Combined with Haorui’s existing products, this will offer complete support to clinical labs, blood centers, and genomics institutions working to create detailed and reliable blood group profiles. Haorui has been a leader in bringing long-read sequencing into clinical practice in China, launching a HiFi-based HLA typing product in 2022 and comprehensive blood group genotyping panels in 2023.

In 2024, Haorui expanded its partnerships with major blood centers to enhance research on rare blood classification and mapping of erythrocyte antigens, which require high-resolution genetic analysis. This growing partnership supports one of the fastest-growing clinical genomics markets globally and highlights a shared commitment to making precise sequencing technologies more accessible for healthcare applications that rely on accurate genomic data at scale.